Key result
In dogs treated with the GPIIb/IIIa antagonist DMP 728, administration of the monoclonal antibody DC11 attenuated the inhibition of platelet aggregation and reduced prolonged bleeding times.
Why the study?
Does the monoclonal antibody DC11 reverse the antiplatelet and bleeding effects of the GPIIb/IIIa antagonist DMP 728 in dogs?
Population
Anesthetized mongrel dogs
Comparison
Monoclonal antibody DC11 given 10 minutes after… vs DMP 728 alone (implied)
Design
Preclinical
Follow-up
up to 4 hours
Authors
Loading...
DC11 may partially reverse GPIIb/IIIa antagonist effects in dogs; leaves open translation to human reversal agents.
Does the monoclonal antibody DC11 reverse the antiplatelet and bleeding effects of the GPIIb/IIIa antagonist DMP 728 in dogs?
The monoclonal antibody DC11 can partially reverse the antiplatelet and bleeding effects of the GPIIb/IIIa antagonist DMP 728 in a canine model.
Reilly et al. (1995) studied Reversal of GPIIb/IIIa receptor blockade. DC11 vs. DMP 728 alone was evaluated on Platelet aggregation and bleeding time. In dogs treated with the GPIIb/IIIa antagonist DMP 728, administration of the monoclonal antibody DC11 attenuated the inhibition of platelet aggregation and reduced prolonged bleeding times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: